Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI258 in advanced urothelial carcinoma by FGFR3 mutation status
NL-OMON36264Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dovitinib in transitional cell carcinoma (TCC) and bladder cancer (2 cohorts), sponsored by Novartis. Primary endpoints: Overall response rate in FGFR3-mutant cohort and Overall response rate in FGFR3-wild-type cohort. Planned start Jun 2010; status: withdrawn.
02
Drugs
dovitinib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON36264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36264.